Αποτελέσματα Αναζήτησης
• RZV was found cost-saving in several immune-compromised populations. ... . 68 The authors further noted that cost-effectiveness models should be updated when new evidence becomes available to support the effect on a potential vaccination ... Cost-effectiveness of Herpes Zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163(7 ...
24 Απρ 2022 · Our developed “asymptomatic” herpes vaccine approach which is based on understanding the immune mechanisms by which seropositive asymptomatic individuals are “naturally” protected from recurrent herpes disease throughout their lives.
25 Ιουλ 2024 · The vaccine should be cost–effective and price should not be a barrier to access, including in LMICs. Dosage, regimen, and cost of goods should be amenable to affordable supply.
5 Μαρ 2024 · There are approved vaccines to prevent STIs, such as mpox and HPV. Currently, there's no cure or preventive vaccine for genital herpes. However, in addition to GSK, companies such as Moderna Inc and BioNTech SE are conducting HSV vaccine research as of March 5, 2024. —
1 Μαΐ 2024 · This Review summarizes the status of therapeutic vaccines for herpes simplex virus, cytomegalovirus, and Epstein-Barr virus and proposes approaches for future development.
We also review what is known of the natural immune control of herpes lesions, via interacting innate immunity and CD4 and CD8 T cells and the lessons they provide for development of new, more effective vaccines.
Researchers have attempted to develop prophylactic and therapeutic vaccines against genital herpes using several vaccine platforms and adjuvants. The adjuvants are primarily used to induce more robust T cell and antibody responses against HSV. As in other vaccines, alum, MF59, MPL, AS04, and QS21 have been used as adjuvants in HSV vaccines
